Bristol Myers Squibb Reports CAR T-Cell Therapy Data In Multiple Sclerosis

Bristol Myers Squibb reported interim Phase 1 Breakfree-2 study results for investigational CAR T-cell therapy zolacabtagene autoleucel (zola-cel) in 66 patients with highly active relapsing and progressive multiple sclerosis. The article provides no efficacy or safety findings, so the direction and significance of the results cannot be assessed.